MetaCap

Adicet Bio (ACET) vs TransCode Therapeutics (RNAZ)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Adicet Bio (ACET) has outperformed TransCode Therapeutics (RNAZ) over the past year, losing 77.8% versus a loss of 86.6%. Over five years, ACET leads with a -98.6% price change compared with -100.0% for RNAZ. TransCode Therapeutics is the larger company by market cap ($20.1 million vs $20.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACET-77.78%RNAZ-86.57%
+49%-22%-93%
Nov 21, 20251 yearNov 20, 2026
ACET-98.56%RNAZ-100.00%
+140%+14%-111%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACET versus RNAZ key metrics
MetricACETRNAZ
Share price$2.14$1.16
Market cap$20.03M$20.07M
1-day change-13.01%-10.77%
YTD return-74.58%-83.02%
1-year return-77.78%-86.57%
5-year return-98.58%-100.00%
EPS (TTM)$-7.53$-47.95
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-116.80M$-34.66M
52-week high$11.15$12.60
52-week low$2.12$1.01
Distance from 52-week high-80.81%-90.79%
Analyst consensusstrong_buy—
Avg. price target upside+1527.57%—
Average volume271.05K52.03K
Shares outstanding9.36M17.30M
Employees10212
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Adicet Bio

ACET stock →

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees

About TransCode Therapeutics

RNAZ stock →

TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

ACET vs RNAZ FAQ

Which is bigger, Adicet Bio or TransCode Therapeutics?

TransCode Therapeutics (RNAZ) is larger, with a market capitalization of $20.07M compared with $20.03M for Adicet Bio (ACET).

Which stock has performed better over the past year, ACET or RNAZ?

ACET returned -77.78% over the past 12 months, compared with -86.57% for RNAZ (price return, excluding dividends). Past performance does not predict future results.

Are Adicet Bio and TransCode Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons